Terns Pharmaceuticals’ $53 Cash Sale to Merck Faces Legal Scrutiny
Terns Pharmaceuticals agreed to sell itself to Merck for $53.00 per share in cash, granting shareholders immediate liquidity. Halper Sadeh LLC has launched an investigation into potential fiduciary breaches and insider benefits, warning that deal terms could limit superior offers and urging shareholders to seek increased consideration.
1. Acquisition Terms
Merck has agreed to acquire Terns Pharmaceuticals for $53.00 per share in cash, positioning the deal as a full acquisition and providing immediate liquidity to Terns shareholders.
2. Legal Investigation
Halper Sadeh LLC is investigating potential violations of securities laws and breaches of fiduciary duties, focusing on insider benefits and deal provisions that may deter superior offers.
3. Shareholder Remedies
The firm may pursue increased deal consideration, request additional disclosures or information, and seek other relief on behalf of shareholders concerned about the transaction’s fairness.
4. Shareholder Actions
Terns shareholders are urged to review their rights and contact Halper Sadeh LLC with no upfront fees under a contingent fee arrangement.